Connection
Frank Scott to Gastrointestinal Agents
This is a "connection" page, showing publications Frank Scott has written about Gastrointestinal Agents.
|
|
Connection Strength |
|
 |
|
 |
|
1.661 |
|
|
|
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.655
-
Scott FI, Johnson FR, Bewtra M, Brensinger CM, Roy JA, Reed SD, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Curtis JR, Lewis JD. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. Inflamm Bowel Dis. 2019 04 11; 25(5):925-936.
Score: 0.603
-
Singh S, Loftus EV, Limketkai BN, Haydek JP, Agrawal M, Scott FI, Ananthakrishnan AN. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024 Dec; 167(7):1307-1343.
Score: 0.223
-
Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn's Disease: a 2016 Update. Curr Gastroenterol Rep. 2016 Sep; 18(9):50.
Score: 0.126
-
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV, Singh S. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology. 2024 Dec; 167(7):1460-1482.
Score: 0.055
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|